RESEARCH TRIANGLE PARK, N.C. (AP) — Drug developer BioCryst Pharmaceuticals Inc.has appointed Thomas Staab to serve as chief financial officer beginning July 1.
His predecessor, Stuart Grant, has agreed to extend his employment another month, through the end of June. Grant has served four years in the CFO post.
Staab served as executive vice president, CFO and treasurer of Inspire Pharmaceuticals from May 2003 through its $430 million acquisition this month by Merck & Co. Before that, he held senior financial positions of acting CFO and treasurer at Triangle Pharmaceuticals, Inc., through its $465 million acquisition by Gilead Sciences, Inc. in 2003.
Before joining Triangle, Staab spent eight years working for PricewaterhouseCoopers LLP providing audit and business advisory services to corporations.
Shares of BioCryst rose 2 cents to close at $3.23.